Key result
Iron-based bioresorbable scaffolds offer ultrathin struts and high radial strength, but long-term comparative efficacy remains unproven.
Answers are grounded in this paper and cite their sources.
Reviews performance and degradation kinetics of iron-based bioresorbable scaffolds, highlighting the need for randomized comparative trials before widespread adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) conducted a review in Coronary artery disease requiring percutaneous coronary intervention. Iron-based bioresorbable drug-eluting coronary scaffold system (IBS, Biotyx) vs. Commercially available bioresorbable scaffolds (Absorb, Magmaris, Freesolve) and drug-eluting stents (Xience Xpedition) was evaluated. Iron-based bioresorbable scaffolds feature ultrathin 55-65 μm struts, ~150 kPa radial strength, and a 24-36 month degradation period, though long-term comparative clinical efficacy remains unproven.
Synapse has enriched 10 related papers. Consider them for comparative context: